BAJAJ BROKING

Notification
No new Notification messages
Inventurus Knowledge Solutions IPO is Open!
Apply for the Inventurus Knowledge Solutions IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
NSE BSE
cipla ltd stock

CIPLA LTD Share Price

1447.3 1.90 (0.13%)
Dec 13 2024 03:30 PM Pharmaceuticals NSE: CIPLA

CIPLA LTD Share Price Update

As of the latest trading session, CIPLA LTD share price is currently at 1447.3, which is up by 1.90 from its previous closing. Today, the stock has fluctuated between 1423.80 and 1449.50. Over the past year, CIPLA LTD has achieved a return of 20.58 %. In the last month alone, the return has been -5.22 %. Read More...

CIPLA LTD Performance

Day Range

Low1423.80 High1449.50
1447.30

52 Week Range

Low 1192.10 High 1702.05
1447.30

CIPLA LTD Share Price

694

500087

CIPLA

img img img img
No Data Available

Open Price

1445.10

Prev. Close

1445.40

Volume (Shares)

1318852.00

Total traded value

19087.74

Upper Circuit

1589.90

Lower Circuit

1300.90

Note: The current prices & values are delayed, Login to your account for live updates.

CIPLA LTD Fundamentals


(Standalone)

Market Cap (Cr) 116850.20
PE Ratio (TTM) 26.63
Book Value / Share 360.73
Beta 0.25
ROE 15.50%
EPS (TTM) 52.42
Dividend Yield 0.90%
Net Profit Qtr (Cr) 1178.16

CIPLA LTD Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition

Revenue

Net income

Particulars SEP 2024 (Values in Cr)
Revenue 3969.86
Operating Expense 3485.70
Net Profit 1178.16
Net Profit Margin (%) 29.67
Earnings Per Share (EPS) 14.59
EBITDA 1727.18
Effective Tax Rate (%) 25.36
Particulars JUN 2024 (Values in Cr)
Revenue 3752.25
Operating Expense 3284.12
Net Profit 1055.94
Net Profit Margin (%) 28.14
Earnings Per Share (EPS) 13.08
EBITDA 1573.38
Effective Tax Rate (%) 26.18
Particulars MAR 2024 (Values in Cr)
Revenue 3444.92
Operating Expense 3351.02
Net Profit 1038.40
Net Profit Margin (%) 30.14
Earnings Per Share (EPS) 12.86
EBITDA 1366.50
Effective Tax Rate (%) 19.78
Particulars DEC 2023 (Values in Cr)
Revenue 3798.31
Operating Expense 3169.54
Net Profit 1114.14
Net Profit Margin (%) 29.33
Earnings Per Share (EPS) 14.99
EBITDA 1524.84
Effective Tax Rate (%) 26.28
Particulars SEP 2023 (Values in Cr)
Revenue 3736.46
Operating Expense 3195.48
Net Profit 1029.69
Net Profit Margin (%) 27.55
Earnings Per Share (EPS) 14.17
EBITDA 1430.46
Effective Tax Rate (%) 26.40
Particulars MAR 2024 (Values in Cr)
Revenue 14441.14
Operating Expense 12698.03
Net Profit 4077.25
Net Profit Margin (%) 28.23
Earnings Per Share (EPS) 50.51
EBITDA 5554.81
Effective Tax Rate (%) 24.91
Particulars MAR 2023 (Values in Cr)
Revenue 13073.53
Operating Expense 11610.63
Net Profit 2513.47
Net Profit Margin (%) 19.22
Earnings Per Share (EPS) 31.15
EBITDA 3623.77
Effective Tax Rate (%) 28.66
Particulars MAR 2022 (Values in Cr)
Revenue 15052.48
Operating Expense 12243.14
Net Profit 2957.93
Net Profit Margin (%) 19.65
Earnings Per Share (EPS) 36.67
EBITDA 4377.93
Effective Tax Rate (%) 24.22
Particulars MAR 2021 (Values in Cr)
Revenue 11060.17
Operating Expense 8748.99
Net Profit 2468.28
Net Profit Margin (%) 22.31
Earnings Per Share (EPS) 30.61
EBITDA 3297.69
Effective Tax Rate (%) 26.55
Particulars MAR 2020 (Values in Cr)
Revenue 12220.22
Operating Expense 10587.68
Net Profit 2318.17
Net Profit Margin (%) 18.96
Earnings Per Share (EPS) 28.76
EBITDA 3600.14
Effective Tax Rate (%) 21.79
Particulars MAR 2024 (Values in Cr)
Book Value / Share 330.79
ROE % 16.58
ROCE % 22.27
Total Debt to Total Equity 0.03
EBITDA Margin 26.55
Particulars MAR 2023 (Values in Cr)
Book Value / Share 290.01
ROE % 12.82
ROCE % 17.79
Total Debt to Total Equity 0.04
EBITDA Margin 23.38
Particulars MAR 2022 (Values in Cr)
Book Value / Share 258.33
ROE % 13.07
ROCE % 16.83
Total Debt to Total Equity 0.08
EBITDA Margin 21.37
Particulars MAR 2021 (Values in Cr)
Book Value / Share 227.25
ROE % 14.09
ROCE % 17.39
Total Debt to Total Equity 0.14
EBITDA Margin 23.58
Particulars MAR 2020 (Values in Cr)
Book Value / Share 195.51
ROE % 10.05
ROCE % 12.19
Total Debt to Total Equity 0.23
EBITDA Margin 20.72
Particulars MAR 2024 (Values in Cr)
Book Value / Share 346.49
ROE % 15.50
ROCE % 20.10
Total Debt to Total Equity 0.00
EBITDA Margin 35.71
Particulars MAR 2023 (Values in Cr)
Book Value / Share 305.25
ROE % 10.66
ROCE % 14.28
Total Debt to Total Equity 0.00
EBITDA Margin 27.84
Particulars MAR 2022 (Values in Cr)
Book Value / Share 279.05
ROE % 13.94
ROCE % 18.21
Total Debt to Total Equity 0.00
EBITDA Margin 28.95
Particulars MAR 2021 (Values in Cr)
Book Value / Share 247.10
ROE % 13.22
ROCE % 17.18
Total Debt to Total Equity 0.00
EBITDA Margin 32.92
Particulars MAR 2020 (Values in Cr)
Book Value / Share 215.85
ROE % 13.97
ROCE % 17.81
Total Debt to Total Equity 0.00
EBITDA Margin 28.44
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 874.97
Total Assets 32717.82
Total Liabilities 32717.82
Total Equity 26802.33
Share Outstanding 807367062
Price to Book Ratio 4.31
Return on Assets (%) 12.59
Return on Capital (%) 15.24
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 1564.62
Total Assets 29463.28
Total Liabilities 29463.28
Total Equity 23713.54
Share Outstanding 807150593
Price to Book Ratio 2.95
Return on Assets (%) 9.50
Return on Capital (%) 11.56
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 1928.48
Total Assets 27101.12
Total Liabilities 27101.12
Total Equity 21117.38
Share Outstanding 806814036
Price to Book Ratio 3.65
Return on Assets (%) 9.28
Return on Capital (%) 11.47
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 1401.23
Total Assets 25151.89
Total Liabilities 25151.89
Total Equity 18585.59
Share Outstanding 806463279
Price to Book Ratio 3.30
Return on Assets (%) 9.56
Return on Capital (%) 11.82
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 1003.91
Total Assets 23662.56
Total Liabilities 23662.56
Total Equity 16057.28
Share Outstanding 806235329
Price to Book Ratio 1.96
Return on Assets (%) 6.53
Return on Capital (%) 8.19
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 333.20
Total Assets 31053.23
Total Liabilities 31053.23
Total Equity 27973.92
Share Outstanding 807367062
Price to Book Ratio 4.31
Return on Assets (%) 13.12
Return on Capital (%) 14.58
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 966.46
Total Assets 27596.47
Total Liabilities 27596.47
Total Equity 24638.09
Share Outstanding 807150593
Price to Book Ratio 2.95
Return on Assets (%) 9.10
Return on Capital (%) 10.2
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 1428.03
Total Assets 25449.05
Total Liabilities 25449.05
Total Equity 22513.55
Share Outstanding 806814036
Price to Book Ratio 3.65
Return on Assets (%) 11.62
Return on Capital (%) 13.14
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 874.80
Total Assets 22963.74
Total Liabilities 22963.74
Total Equity 19927.56
Share Outstanding 806463279
Price to Book Ratio 3.30
Return on Assets (%) 10.74
Return on Capital (%) 12.39
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 523.07
Total Assets 20405.66
Total Liabilities 20405.66
Total Equity 17402.96
Share Outstanding 806235329
Price to Book Ratio 1.96
Return on Assets (%) 11.36
Return on Capital (%) 13.32
Particulars MAR 2024 (Values in Cr)
Net Income 5896.72
Cash from Operations 5731.39
Cash from Investing -2988.03
Cash from Financing -1200.43
Net change in Cash -54.55
Free Cash Flow 6829.64
Particulars MAR 2023 (Values in Cr)
Net Income 4220.77
Cash from Operations 4539.54
Cash from Investing -2388.51
Cash from Financing -958.29
Net change in Cash -109.15
Free Cash Flow 5380.07
Particulars MAR 2022 (Values in Cr)
Net Income 3675.39
Cash from Operations 4465.40
Cash from Investing -1871.88
Cash from Financing -1599.79
Net change in Cash -145.77
Free Cash Flow 5009.50
Particulars MAR 2021 (Values in Cr)
Net Income 3290.06
Cash from Operations 4792.63
Cash from Investing -2387.18
Cash from Financing -1239.51
Net change in Cash 128.51
Free Cash Flow 5422.29
Particulars MAR 2020 (Values in Cr)
Net Income 2178.18
Cash from Operations 3916.70
Cash from Investing 104.04
Cash from Financing -2948.82
Net change in Cash 223.67
Free Cash Flow 4489.46
Particulars MAR 2024 (Values in Cr)
Net Income 5432.14
Cash from Operations 4950.93
Cash from Investing -2882.82
Cash from Financing -708.83
Net change in Cash 135.12
Free Cash Flow 5501.42
Particulars MAR 2023 (Values in Cr)
Net Income 3685.17
Cash from Operations 4119.31
Cash from Investing -2757.95
Cash from Financing -424.77
Net change in Cash -147.67
Free Cash Flow 4705.71
Particulars MAR 2022 (Values in Cr)
Net Income 3905.08
Cash from Operations 3707.46
Cash from Investing -2463.73
Cash from Financing -426.72
Net change in Cash -117.02
Free Cash Flow 4012.50
Particulars MAR 2021 (Values in Cr)
Net Income 3350.66
Cash from Operations 4412.26
Cash from Investing -3360.45
Cash from Financing -65.80
Net change in Cash 34.06
Free Cash Flow 4929.23
Particulars MAR 2020 (Values in Cr)
Net Income 2964.31
Cash from Operations 2683.12
Cash from Investing -1126.33
Cash from Financing -693.89
Net change in Cash 197.92
Free Cash Flow 3132.83
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 65.57 37.68 3.57 502.48 37.54 / 77.70
BLISS GVS PHARMA LTD 173.80 21.75 1.81 1830.67 92.25 / 175.80
FERMENTA BIOTECH LIMITED 406.80 141.25 4.12 1197.25 145.00 / 440.00
GLAXOSMITHKLINE PHARMA LT 2306.65 48.74 23.36 39076.04 1668.20 / 3087.95
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 65.57 57.02 11.14 502.48 37.54 / 77.70
AMRUTAJAN HEALTH LTD 751.60 45.72 7.29 2172.92 556.05 / 861.40
ASTRAZENECA PHARMA IND LT 6636.00 128.88 24.42 16590.00 4050.15 / 8139.85
BLISS GVS PHARMA LTD 173.80 22.66 1.78 1830.67 92.25 / 175.80

Technicals

  • EMA & SMA
  • Resistance and Support
  • Price Change Analysis
- redarrow -
red-green-graph indicator
Bullish Moving Averages -
Bearish Moving Averages -
  • 5 Days 1460.40
  • 26 Days 1503.90
  • 10 Days 1474.60
  • 50 Days 1531.00
  • 12 Days 1477.60
  • 100 Days 1537.70
  • 20 Days 1487.60
  • 200 Days 1459.90
1456.67
PIVOT
First Resistance 1465.33
Second Resistance 1476.57
Third Resistance 1485.23
First Support 1445.43
Second Support 1436.77
Third Support 1425.53
RSI 37.28
MACD -26.27
Commodity Channel Index (CCI) -149.52
ADX 23.94
Williams % R -93.86

Over 1 Month

down

-5.22

Over 3 Months

down

-12.78

Over 6 Months

down

-6.20

Over 1 Year

down

20.58

Over 3 Years

down

17.48

Over 5 Years

down

25.67

CIPLA LTD Future

Future: Price

26 Dec
1452.00
30 Jan
1463.05
27 Feb
1474.00
25 May
0 100 200 300 400 500 600

Discount/Premium

26 Dec
4.70
30 Jan
15.75
27 Feb
26.70
25 May
0 1 2 3 4 5 6 7

Active Calls

1440.0
4606
1500.0
3938
1460.0
3911
25 May
0 500 1000 1500 2000 2500 3000

Active Puts

1400.0
2347
1420.0
2258
1440.0
2107
25 Jul
0 500 1000 1500 2000 2500

CIPLA LTD Shareholding Pattern

  • Shareholding Summary
  • Historical Promotor Holding
  • Historical MF Holding
  • Historical FII Holding

Holding

Public
16.11
Promoter Holdings
30.92
FII
28.79
DII
24.16
Promoter Shares(Pledge Percentage)
0.0
Name Category Shares Shares%
Yusuf Khwaja Hameid Shareholding of Promoter and Promoter Group 1.50521183E8 18.68
Sophie Ahmed Shareholding of Promoter and Promoter Group 4.5982E7 5.71
Hdfc Mutual Fund-hdfc Arbitrage Fund Public Shareholding 4.1176157E7 5.11
M K Hamied Shareholding of Promoter and Promoter Group 2.784432E7 3.46
Lici Money Plus Balanced Fund Public Shareholding 2.5190429E7 3.13
Sbi Arbitrage Opportunities Fund Public Shareholding 2.2122027E7 2.75
Government Pension Fund Global Public Shareholding 1.700486E7 2.11
Nps Trust Public Shareholding 1.1343347E7 1.41
Kamil Hamied Shareholding of Promoter and Promoter Group 1.09395E7 1.36
Samina Hamied Shareholding of Promoter and Promoter Group 8954750.0 1.11
Icici Prudential Equity Arbitrage Fund Public Shareholding 8938390.0 1.11
Uti Nifty 50 Index Fund Public Shareholding 8405817.0 1.04
Kotak Equity Hybrid Public Shareholding 8301172.0 1.03
Rumana Hamied Shareholding of Promoter and Promoter Group 4943250.0 0.61
Farida Hamied Shareholding of Promoter and Promoter Group 0.0 0.0
Okasa Pharma Private Limited Shareholding of Promoter and Promoter Group 0.0 0.0
Hamsons Laboratories Llp Shareholding of Promoter and Promoter Group 0.0 0.0
Alps Remedies Private Limited Shareholding of Promoter and Promoter Group 0.0 0.0
Shree Riddhi Chemicals Llp Shareholding of Promoter and Promoter Group 0.0 0.0
Mn Rajkumar Garments Llp Shareholding of Promoter and Promoter Group 0.0 0.0
Shirin Hamied Shareholding of Promoter and Promoter Group 0.0 0.0

CIPLA LTD

  • Dividend
  • Bonus
  • Split
Ex-Date Dividend Amt. Dividend Type Record Date Instrument Type
2024-08-02 13.0 Final 2024-08-02 Equity shares 2023-07-21 8.5 Final 2023-07-21 Equity shares 2022-08-08 5.0 Final 2022-08-10 Equity shares 2021-08-09 5.0 Final 2021-08-11 Equity shares 2020-03-19 3.0 Interim 2020-03-20 Equity shares 2020-03-19 1.0 Special 2020-03-20 Equity shares 2019-07-31 3.0 Final 2019-08-02 Equity shares 2018-08-13 3.0 Final 2018-08-16 Equity shares 2017-07-26 2.0 Final 2017-07-28 Equity shares 2016-09-12 2.0 Final 2016-09-15 Equity shares 2015-08-11 2.0 Final 2015-08-13 Equity shares 2014-08-06 2.0 Final 2014-08-08 Equity shares 2013-08-06 2.0 Final 2013-08-08 Equity shares 2012-08-01 2.0 Final 2012-08-03 Equity shares 2011-08-09 2.0 Final 2011-08-11 Equity shares 2010-09-03 0.8 Interim 2010-09-06 Equity shares 2010-07-23 2.0 Final 2010-07-27 Equity shares 2009-08-10 2.0 Final 2009-08-12 Equity shares 2008-08-12 2.0 Final 2008-08-14 Equity shares 2007-08-08 2.0 Final 2007-08-10 Equity shares 2006-08-18 0.0 Final 2006-08-22 Equity shares 2005-08-19 0.0 Final 2005-08-23 Equity shares
Ex-Date Ex-Bonus Ratio
2006-04-25 2006-04-24 3:2 1999-11-05 1999-10-18 2:1
Ex-Date Old FV NEW FV Record Date
2004-05-11 10.0 2.0 2004-05-19

Cipla Limited Overview

Cipla, established in 1990, is a leading pharmaceutical entity in India, holding significant market positions in therapies like respiratory and urology, and a broad product portfolio of over 1,500 products across 65 therapeutic categories. With a strong footprint in India and a significant presence in emerging markets, Cipla has become the 3rd largest pharmaceutical company in India and a major exporter. The company's expertise in manufacturing generic APIs, with over 200 generics supplied to 62 countries, underlines its role as a preferred partner globally. Cipla's manufacturing prowess is supported by 47 state-of-the-art facilities across six countries, enabling a diversified product range from antidepressants to antivirals. Strategic partnerships for COVID-19 treatments with major pharmaceutical companies, acquisitions to bolster renewable energy initiatives, and a joint venture for biologic product development illustrate Cipla's forward-looking approach. With subsidiaries streamlined for operational efficiency and a scheme of arrangement to optimise its business structure, Cipla invests heavily in R&D, underscoring its commitment to innovation. As it aims to expand its lung specialty offerings, Cipla continues to deepen its focus on antidiabetics and oncology, aiming to partner with global corporations to enhance its market reach and therapeutic impact.

Cipla Share Result Highlights

Metric

Figure

Share Price (NSE)

₹1579.50 (Nov 8, 2024)

Market Cap

₹127,523.60 Cr (Nov 2024)

Day Range

₹1568.70 - ₹1584.00 (Nov 8, 2024)

52-Week Range

₹1164.55 - ₹1702.05 (2024)

Volume (Shares)

5,07,652 (Nov 8, 2024)

PE Ratio (TTM)

28.96 (2024)

Earnings Per Share (EPS)

₹52.43 (2024)

Dividend Yield

0.83% (2024)

Net Profit Margin

29.67% (Q2 Sep 2024)

Effective Tax Rate

25.36% (Q2 Sep 2024)

Key Highlights

  • Cipla share price at ₹1579.50 (Nov 8, 2024), demonstrating resilience within the 52-week range.

  • Market cap of ₹127,523.60 Cr (Nov 2024), illustrating Cipla's industry position.

  • Strong net profit margin of 29.67% (Q2 Sep 2024).

  • Dividend yield of 0.83% (2024), ensuring shareholder value.

Cipla Share Annual Reports

Metric

Figure

Annual Revenue

₹3969.86 Cr (Sep 2024)

Net Profit

₹1178.16 Cr (Sep 2024)

Operating Expense

₹3485.70 Cr (Sep 2024)

EBITDA

₹1727.18 Cr (Sep 2024)

Net Profit Margin (%)

29.67% (Q2 Sep 2024)

Return on Equity (ROE)

15.50% (2024)

Book Value per Share

₹360.74 (2024)

Key Highlights

  • Annual revenue rose to ₹3969.86 Cr by Sep 2024, reflecting Cipla's consistent upward trend in revenue.

  • Net profit was a solid ₹1178.16 Cr in Sep 2024, indicating strong financial resilience.

  • Achieved EBITDA of ₹1727.18 Cr in Sep 2024, demonstrating operational efficiency.

  • Return on Equity (ROE) at 15.50% for 2024 emphasises significant value for shareholders.

Cipla Share Dividend

Dividend Type

Dividend Amount

Ex-Date

Record Date

Final Dividend

₹13 per share

02 Aug 2024

02 Aug 2024

Final Dividend

₹8.5 per share

21 Jul 2023

21 Jul 2023

Final Dividend

₹5 per share

08 Aug 2022

10 Aug 2022

Final Dividend

₹5 per share

09 Aug 2021

11 Aug 2021

Interim Dividend

₹3 per share

19 Mar 2020

20 Mar 2020

Special Dividend

₹1 per share

19 Mar 2020

20 Mar 2020

Key Highlights

  • Cipla share price benefits from consistent dividends, ensuring value for shareholders.

  • The recent final dividend of ₹13 per share was issued on 02 Aug 2024.

  • A prior final dividend of ₹8.5 per share was distributed on 21 July 2023.

  • Cipla has rewarded investors with special dividends, like ₹1 per share on 19 Mar 2020.

About CIPLA LTD

Read More
  • Management structure
  • Board of directors
  • Committees of the board of directors

Companies Owned by CIPLA LTD

Learn More About Stocks

We have something for everyone

Explore More Investment Options

Stocks

Secure and enhance your financial future today

investment-card-icon

IPOs

Your gateway to future financial opportunities

investment-card-icon

MTF

Explore Buy Now Pay Later and boost your capital by up to 4x  

investment-card-icon

US Stocks

Discover opportunities to invest in elite FAANG stocks

investment-card-icon

Additional FAQs

1. Who is the CEO of Cipla Ltd?

The CEO of Cipla Ltd is Umang Vohra, who has held the position of Managing Director and Global Chief Executive Officer (MD and GCEO) since September 2016. His leadership is instrumental in driving Cipla’s strategic growth in the pharmaceutical sector.

 

2. When was Cipla Ltd established?

Cipla Ltd was established in 1935, marking its presence in the pharmaceutical industry for nearly a century. Its foundation has enabled it to become a respected and influential player with a long-standing history.

 

3. What factors influence the Cipla Share Price?

The Cipla share price is influenced by several factors, including quarterly earnings, overall sector performance, regulatory changes, and economic conditions. Investor sentiment, competitive landscape, and global healthcare trends also play a significant role.

 

4. Is Cipla Ltd debt free?

Cipla Ltd is not entirely debt-free; the company manages a balanced financial structure that includes both debt and equity. This approach enables Cipla to fund growth initiatives while maintaining financial flexibility in a competitive market.

 

5. What is the CAGR of Cipla Share?

The CAGR for Cipla shares varies by timeframe: over the past 10 years, it stands at 9%, over 5 years at 28%, over 3 years at 20%, and in the past year at 27%, reflecting robust growth in recent periods.

 

6. How has the Cipla Share Price performed over the past year?

The Cipla share price has shown strong performance, with a 1-year CAGR of 27%. This growth reflects Cipla’s operational achievements and investor confidence, showcasing the stock's resilience and value appreciation over the last year.

Frequently Asked Questions

What is the Share Price of Cipla Ltd?

Answer Field

The share price of Cipla Ltd for NSE is ₹ 1447.3 and for BSE is ₹ 1447.35.

What is the Market Cap of Cipla Ltd?

Answer Field

The market cap of Cipla Ltd for NSE is ₹ 11,68,50.20 Cr. and for BSE is ₹ 11,68,54.30 Cr. as of now.

What is the 52 Week High and Low of Cipla Ltd?

Answer Field

The 52 Week High and Low of Cipla Ltd for NSE is ₹ 1702.05 and ₹ 1192.10 and for BSE is ₹ 1702.00 and ₹ 1192.85.

How to Buy Cipla Ltd share?

Answer Field

You can trade in Cipla Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Cipla Ltd?

Answer Field

The 1 year returns on the stock has been 20.58%.

What is the Current Share Price of Cipla Ltd?

Answer Field

Cipla Ltd share price is for NSE ₹ 1447.3 & for BSE ₹ 1447.35 as on Dec 13 2024 03:30 PM.

What is the Market Cap of Cipla Ltd Share?

Answer Field

The market cap of Cipla Ltd for NSE ₹ 11,68,50.20 & for BSE ₹ 11,68,54.30 as on Dec 13 2024 03:30 PM.

What is the P/E Ratio of Cipla Ltd Share?

Answer Field

As on Dec 13 2024 03:30 PM the price-to-earnings (PE) ratio for Cipla Ltd share is 26.63.

What is the PB ratio of Cipla Ltd Share?

Answer Field

As on Dec 13 2024 03:30 PM, the price-to-book (PB) ratio for Cipla Ltd share is 360.73.

How to Buy Cipla Ltd Share?

Answer Field

You can trade in Cipla Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Cipla Ltd Share on Bajaj Broking App?

Answer Field

To buy Cipla Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Cipla Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

8 Lacs+ Users

icon-with-text

4.4+ App Rating

icon-with-text

4 Languages

icon-with-text

₹4700+ Cr MTF Book

icon-with-text
loader